A simplified process flow with associated definitions for pharmaceutical sampling and testing is proposed.
ipopba - Stock.adobe.com
For pharma companies and regulators to have meaningful discussion on the results of analyses, they should first agree on the meaning of the terms used. As detailed in Part 1 of this paper, the pharmaceutical industry currently does not have a globally agreed nomenclature for sampling and testing.
Inconsistent sampling and testing processes that may result from this lack of standardized practices can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.
In the second part of this paper, the author proposes a simplified overall process flow with associated definitions for pharmaceutical sampling and testing.
Read this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.
Chris Burgess is managing director, Burgess Analytical Consultancy Limited, Barnard Castle, Co Durham, UK.
Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 34–40
When referring to this article, please cite it as C. Burgess, “Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.